Search

Your search keyword '"Icardi G"' showing total 562 results
Start Over Author "Icardi G"
562 results on '"Icardi G"'

1. Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection

Author

Rosso R, Bernardini C, Bruzzone B, Secondo G, Icardi G, Viscoli C, and Di Biagio A

Subjects
vertically acquired HIV-1 infection, multidrug resistance, adherence, darunavir, etravirine, Medicine
Abstract

Abstract Multiclass-drug resistance, often caused by poor treatment compliance, is a challenging problem in all categories of HIV-infected patients. Selective pressure is higher in youth for both biological and behavioral reasons. We report the case of a 15-year-old Caucasian male, with vertically acquired HIV-1 infection, who failed several lines of antiretroviral therapy and was successfully treated with darunavir/ritonavir and etravirine.

Published
2009
Full Text
View/download PDF

7. COVID-19: opinions and behavior of Italian general population during the first epidemic phase

Author

Genovese, C., La Fauci, V., Di Pietro, A., Trimarchi, G., Odone, A., Casuccio, A., Costantino, C., Restivo, V., Fantini, M., Gori, D., Azzara, A., Deiana, G., Castaldi, S., Righi, E., Palandri, L., Panciroli, G., Bianco, A., Licata, F., Cosentino, S., Mistretta, A., Marranzano, M., Ragusa, R., Gabutti, G., Stefanati, A., Prato, R., Fortunato, F., Martinelli, D., Icardi, G., Panatto, D., Amicizia, D., Fabiani, L., Moretti, A., Di Risio, D., Siliquini, R., Voglino, G., Bert, F., Lorini, C., Bonaccorsi, G., Torre, I., Pennino, F., Pavia, M., Di Giuseppe, G., Paolantonio, A., Villari, P., Marzuillo, C., Messina, G., Rivieri, C., Nante, N., Majori, S., Tardivo, S., Moretti, F., D'Amato, S., Mazzitelli, F., Giunta, I., Lo Giudice, D., Panto, G., Signorelli, C., Squeri, R., Genovese, Cristina, La Fauci, Vincenza, Di Pietro, Angela, Trimarchi, Giuseppe, Odone, Anna, Casuccio, Alessandra, Costantino, Claudio, Restivo, Vincenzo, Fantini, Mariapia, Gori, Davide, Azara, Antonio, Deiana, Giovanna, Castaldi, Silvana, Righi, Elena, Palandri, Lucia, Panciroli, Giovanni, Bianco, Aida, Licata, Francesca, Cosentino, Sofia, Mistretta, Antonio, Marranzano, Marina, Ragusa, Rosalia, Gabutti, Giovanni, Stefanati, Armando, Prato, Rosa, Fortunato, Francesca, Martinelli, Domenico, Icardi, Giancarlo, Panatto, Donatella, Amicizia, Daniela, Fabiani, Leila, Moretti, Annalucia, Di Risio, Damiana, Siliquini, Roberta, Voglino, Gianluca, Bert, Fabrizio, Lorini, Chiara, Bonaccorsi, Guglielmo, Torre, Ida, Pennino, Francesca, Pavia, Maria, Di Giuseppe, Gabriella, Paolantonio, Andrea, Villari, Paolo, Marzuillo, Carolina, Messina, Gabriele, Rivieri, Cesare, Nante, Nicola, Majori, Silvia, Tardivo, Stefano, Moretti, Francesca, D'Amato, Smeralda, Mazzitelli, Francesco, Giunta, Ioselita, Lo Giudice, Daniela, Pantò, Giuseppe, Signorelli, Carlo, Squeri, Raffaele, Genovese C., La Fauci V., Di Pietro A., Trimarchi G., Odone A., Casuccio A., Costantino C., Restivo V., Fantini M., Gori D., Azzara A., Deiana G., Castaldi S., Righi E., Palandri L., Panciroli G., Bianco A., Licata F., Cosentino S., Mistretta A., Marranzano M., Ragusa R., Gabutti G., Stefanati A., Prato R., Fortunato F., Martinelli D., Icardi G., Panatto D., Amicizia D., Fabiani L., Moretti A., Di Risio D., Siliquini R., Voglino G., Bert F., Lorini C., Bonaccorsi G., Torre I., Pennino F., Pavia M., Di Giuseppe G., Paolantonio A., Villari P., Marzuillo C., Messina G., Rivieri C., Nante N., Majori S., Tardivo S., Moretti F., D'amato S., Mazzitelli F., Giunta I., Lo Giudice D., Panto G., Signorelli C., and Squeri R.

Subjects
risk perception, Male, knowledge, SARS-CoV-2, attitude, COVID-19, perception, population, attitude, COVID-19, knowledge, perception, population, risk perception, Attitude, Humans, Female, Public Health, Epidemics, Human
Abstract

Background and aim: On January 9, 2020, the World Health Organization (WHO) declared that Chinese health authorities had identified a new coronavirus strain never before isolated in humans, the 2019-nCoV later redefined SARS-CoV-2, that still today represent a public health problem. The present survey started on 10 February 2020 with the aim of a) assessing the risk perception in healthcare workers and young students, following the evolution of attitudes, perception and knowledge over time, b) provide useful information to the general population during survey. Results: A study sample consisting of 4116 Italian in-dividuals of both sexes was enrolled. High levels of risk perception, low perception of self-efficacy and low levels of knowledge scores (24.55 ± 5.76 SD) were obtained indicating the need for continuous population monitoring as well as further communication strategies carried out at institution levels. Conclusion: The results of the present study could help public health authorities in carrying out informative campaigns for general population and could be an important tool in evaluating public knowledge and misperceptions during the management of the COVID-19. (www.actabiomedica.it).

Published
2022

8. Immunogenicity and safety of a quadrivalent high-dose inactivated influenza vaccine compared with a standard-dose quadrivalent influenza vaccine in healthy people aged 60 years or older: a randomized Phase III trial

Author

Pepin S., Nicolas J. -F., Szymanski H., Leroux-Roels I., Schaum T., Bonten M., Icardi G., Shrestha A., Tabar C., Van Damme P., Donazzolo Y., Launay O., Schurholz T., Sturm K., Toursarkissian N., Schenkenberger I., Vitale F., Brzostek J., Pajek B., Miszczak-Kowalska E., Khoury R., Grosbois M. -A., Gauby C., Lacroix I., Souzy F., Pandey A., Yandle S., Lupinsky N., Goulet F., Milcamps L., De Sousa J., Lardon M., Lyko V., Blattmann A., Janosczyk H., Samson S., De Bruijn I., Pepin S., Nicolas J.-F., Szymanski H., Leroux-Roels I., Schaum T., Bonten M., Icardi G., Shrestha A., Tabar C., Van Damme P., Donazzolo Y., Launay O., Schurholz T., Sturm K., Toursarkissian N., Schenkenberger I., Vitale F., Brzostek J., Pajek B., Miszczak-Kowalska E., Khoury R., Grosbois M.-A., Gauby C., Lacroix I., Souzy F., Pandey A., Yandle S., Lupinsky N., Goulet F., Milcamps L., De Sousa J., Lardon M., Lyko V., Blattmann A., Janosczyk H., Samson S., and De Bruijn I.

Subjects
safety, Adult, IMPACT, Influenza vaccine, Immunology, immunogenicity, Antibodies, Viral, Quadrivalent Influenza Vaccine, older adult, Immunogenicity, Vaccine, Double-Blind Method, Influenza, Human, Medicine and Health Sciences, Immunology and Allergy, Medicine, Humans, Vaccines, Combined, older adults, Pharmacology, business.industry, Immunogenicity, ADULTS, Hemagglutination Inhibition Tests, EFFICACY, Virology, influenza vaccination, High-dose influenza vaccine, Vaccines, Inactivated, Influenza Vaccines, Phase III trial, business
Abstract

A quadrivalent high-dose inactivated influenza vaccine (IIV4-HD) is licensed for adults ≥65y of age based on immunogenicity and efficacy studies. However, IIV4-HD has not been evaluated in adults aged 60–64y. This study compared immunogenicity and safety of IIV4-HD with a standard-dose quadrivalent influenza vaccine (IIV4-SD) in adults aged ≥60y. This Phase III, randomized, modified double-blind, active-controlled study enrolled 1,528 participants aged ≥60y, randomized 1:1 to a single injection of IIV4-HD or IIV4-SD. Hemagglutination inhibition (HAI) geometric mean titers (GMTs) were measured at baseline and D 28 and seroconversion assessed. Safety was described for 180d after vaccination. The primary immunogenicity objective was superiority of IIV4-HD versus IIV4-SD, for all four influenza strains 28d post vaccination in participants aged 60–64 and ≥65y. IIV4-HD induced a superior immune response versus IIV4-SD in terms of GMTs in participants aged 60–64 y and those aged ≥65y for all four influenza strains. IIV4-HD induced higher GMTs in those aged 60–64 y than those aged ≥65 y. Seroconversion rates were higher for IIV4-HD versus IIV4-SD in each age-group for all influenza strains. Both vaccines were well tolerated in participants ≥60y of age, with no safety concerns identified. More solicited reactions were reported with IIV4-HD than with IIV4-SD. IIV4-HD provided superior immunogenicity versus IIV4-SD and was well tolerated in adults aged ≥60 y. IIV4-HD is assumed to offer improved protection against influenza compared with IIV4-SD in adults aged ≥60 y, as was previously assessed for adults aged ≥65y.

Published
2021

9. Prevalence and Clinical Significance of Persistent Viral Shedding in Hospitalized Adult Patients with SARS-CoV-2 Infection: A Prospective Observational Study

Author

Vena, A., Taramasso, L., Di Biagio, A., Mikulska, M., Dentone, C., De Maria, A., Magnasco, L., Nicolini, L. A., Bruzzone, B., Icardi, G., Orsi, A., Pelosi, P., Ball, L., Battaglini, D., Brunetti, I., Loconte, M., Patroniti, N. A., Robba, C., Bavastro, M., Cerchiaro, M., Giacobbe, D. R., Schiavetti, I., Berruti, M., Bassetti, M., Alessandrini, A., Camera, M., Delfino, E., Dodi, F., Ferrazin, A., Mazzarello, G., Nicolini, L., Toscanini, F., Balletto, E., Portunato, F., Schenone, E., Rosseti, N., Baldi, F., Briano, F., Dettori, S., Labate, L., Mirabella, M., Pincino, R., Russo, C., Sarteschi, G., Sepulcri, C., Tutino, S., Pontremoli, R., Beccati, V., Casciaro, S., Casu, M., Gavaudan, F., Ghinatti, M., Gualco, E., Leoncini, G., Pitto, P., and Salam, K.

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Multivariate analysis, medicine.medical_treatment, 030106 microbiology, law.invention, 03 medical and health sciences, 0302 clinical medicine, law, Internal medicine, Clinical endpoint, medicine, Clinical significance, 030212 general & internal medicine, Viral shedding, Original Research, Outcome, Mechanical ventilation, Univariate analysis, IL-6, COVID-19, SARS-CoV-2, business.industry, Immunosuppression, Intensive care unit, Infectious Diseases, business
Abstract

Background The goal of this study was to investigate the prevalence and factors associated with persistent viral shedding (PVS) in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Methods This was a prospective observational study including all consecutive adults hospitalized with SARS-CoV-2 infection. When the first nasopharyngeal swab was positive for SARS-CoV-2 RNA (day 0), additional samples were obtained on days + 3, + 5, + 7 and then once every 7 days until virus detection was negative. PVS was defined as the duration of shedding of at least 21 days after diagnosis. The primary endpoint of this study was the prevalence of PVS. Results Data were obtained regarding 121 consecutive hospitalized patients with SARS-CoV-2 infection (median age 66 years, male sex 65.3%). Overall, the prevalence of PVS was 38% (46/121 patients). According to univariate analysis, factors associated with PVS were immunosuppression (6.7% vs 21.7%, p = 0.02), increased interleukin-6 (IL-6) levels (≥ 35 ng/ml) at the time of diagnosis (43.4% vs 67.3%, p = 0.02), time from onset of symptoms to diagnosis (median days 7.0 vs 3.5, p = 0.001), intensive care unit admission (22.7% vs 43.5%, p = 0.02), and need for invasive mechanical ventilation (20.0% vs 41.3%, p = 0.01). The multivariate analysis indicated that immunosuppression, increased IL-6 levels at the time of diagnosis, time from onset of symptoms to diagnosis, and need for mechanical ventilation were independent factors associated with PVS. Conclusions PVS was detected in up to 38% of hospitalized patients with SARS-CoV-2 infection and was strongly associated with immunosuppression, increased IL-6 levels, and the need for mechanical ventilation. Supplementary Information The online version contains supplementary material available at 10.1007/s40121-020-00381-8.

Published
2021

11. Co-circulation of SARS-CoV-2 Alpha and Gamma variants in Italy, February and March 2021

Author

Stefanelli, P., Trentini, F., Guzzetta, G., Marziano, V., Mammone, A., Schepisi, M. S., Poletti, P., Grane, C. M., Manica, M., del Manso, M., Andrianou, X., Ajelli, M., Rezza, G., Brusaferro, S., Merler, S., Di Martino, A., Ambrosio, L., Lo Presti, A., Fiore, S., Fabiani, C., Benedetti, E., Di Mario, G., Facchini, M., Puzelli, S., Calzoletti, L., Fontana, S., Venturi, G., Fortuna, C., Marsili, G., Amendola, A., Stuppia, L., Savini, G., Picerno, A., Lopizzo, T., Dell'Edera, D., Minchella, P., Greco, F., Viglietto, G., Atripaldi, L., Limone, A., D'Agaro, P., Licastro, D., Pongolini, S., Sambri, V., Dirani, G., Zannoli, S., Affanni, P., Colucci, M. E., Capobianchi, M. R., Icardi, G., Bruzzone, B., Lillo, F., Orsi, A., Pariani, E., Baldanti, F., Molecolare, U. V., Gismondo, M. R., Maggi, F., Caruso, A., Ceriotti, F., Boniotti, M. B., Barbieri, I., Bagnarelli, P., Menzo, S., Garofalo, S., Scutella, M., Pagani, E., Collini, L., Ghisetti, V., Brossa, S., Ru, G., Bozzetta, E., Chironna, M., Parisi, A., Rubino, S., Serra, C., Piras, G., Coghe, F., Vitale, F., Tramuto, F., Scalia, G., Palermo, C. I., Mancuso, G., Pollicino, T., Di Gaudio, F., Vullo, S., Reale, S., Cusi, M. G., Rossolini, G. M., Pistello, M., Mencacci, A., Camilloni, B., Severini, S., Di Benedetto, M., Terregino, C., Monne, I., Biscaro, V., Stefanelli P, Trentini F, Guzzetta G, Marziano V, Mammone A, Sane Schepisi M, Poletti P, Molina Grané C, Manica M, Del Manso M, Andrianou X, Ajelli M, Rezza G, Brusaferro S, Merler S, Vitale F, Tramuto F, Stefanelli P., Trentini F., Guzzetta G., Marziano V., Mammone A., Sane Schepisi M., Poletti P., Molina Grane C., Manica M., Del Manso M., Andrianou X., Ajelli M., Rezza G., Brusaferro S., Merler S., Sambri V, and (membro del COVID-19 National Microbiology Surveillance Study Group)

Subjects
Epidemiology, SARS-CoV-2, Public Health, Environmental and Occupational Health, COVID-19, co-circulation, lineage, SARS-CoV-2 variant of concern, transmissibility, Humans, Italy, Models, Theoretical, Settore MED/42 - Igiene Generale E Applicata, SARS-COV-2 VARIANT OF CONCERN, CO-CIRCULATION, LINEAGE, TRANSMISSIBILITY, HUMANS, ITALY, MODELS, THEORETICAL, COVID-19, SARS-COV-2, Theoretical, Models, Virology, Human
Abstract

Background Several SARS-CoV-2 variants of concern (VOC) have emerged through 2020 and 2021. There is need for tools to estimate the relative transmissibility of emerging variants of SARS-CoV-2 with respect to circulating strains. Aim We aimed to assess the prevalence of co-circulating VOC in Italy and estimate their relative transmissibility. Methods We conducted two genomic surveillance surveys on 18 February and 18 March 2021 across the whole Italian territory covering 3,243 clinical samples and developed a mathematical model that describes the dynamics of co-circulating strains. Results The Alpha variant was already dominant on 18 February in a majority of regions/autonomous provinces (national prevalence: 54%) and almost completely replaced historical lineages by 18 March (dominant across Italy, national prevalence: 86%). We found a substantial proportion of the Gamma variant on 18 February, almost exclusively in central Italy (prevalence: 19%), which remained similar on 18 March. Nationally, the mean relative transmissibility of Alpha ranged at 1.55–1.57 times the level of historical lineages (95% CrI: 1.45–1.66). The relative transmissibility of Gamma varied according to the assumed degree of cross-protection from infection with other lineages and ranged from 1.12 (95% CrI: 1.03–1.23) with complete immune evasion to 1.39 (95% CrI: 1.26–1.56) for complete cross-protection. Conclusion We assessed the relative advantage of competing viral strains, using a mathematical model assuming different degrees of cross-protection. We found substantial co-circulation of Alpha and Gamma in Italy. Gamma was not able to outcompete Alpha, probably because of its lower transmissibility.

Published
2022

12. Igiene, Medicina Preventiva, Sanità Pubblica

Author

Barbuti, S, Fara, Gm, Giammanco, G, Azara, Aa, Baldo, V, Borella, P, Castiglia, Pg, Coniglio, Ma, Contu, P, Delia, Sa, Donato, F, Faggiano, F, Gabutti, G, Icardi, G, Izzotti, A, Laganà, P, Montagna, Mt, Napoli, C, Orsi, Gb, Privitera, G, Pulliero, A, Sardu, C, Stracci, F, and Vinceti, M

Published
2022

13. Characteristics of SARS-CoV-2 variants of concern B.1.1.7, B.1.351 or P.1: data from seven EU/EEA countries, weeks 38/2020 to 10/2021

Author

Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A. K., Abdelrahman T., Riccardo F., Stefanelli P., Di Martino A., Bella A., Lo Presti A., Casaca P., Moreno J., Borges V., Isidro J., Ferreira R., Gomes J. P., Dotsenko L., Suija H., Epstein J., Sadikova O., Sepp H., Ikonen N., Savolainen-Kopra C., Blomqvist S., Mottonen T., Helve O., Gomes-Dias J., Adlhoch C., Macori G., Russell L., Yandle Z., Bennett C., O'Byrne E., Murphy A., Tuite G., Conroy A., Duffy M., Morley U., Keoghan B., Ford I., Kennedy M., McDonnell S., Flynn A., Clarke A., Crowley A., Martin C., Kelly E., Foxton J., Hare D., Dunford L., Connell J., Moran J., Dean J., Fanning S., Rajan L., De Gascun C., Kenny J., Cotter P., Walsh C., Lawton E., Fitzpatrick A., Mullins E., Della Bartola M., McCabe M., Stapleton P., Meaney C., Fanning L., Prentice M., MacSharry J., Dempsey C., Mallon P., Leon A., Chaturvedi A., Coughlan S., McAndrew G., Reddington K., Walsh F., Fitzpatrick D., Smyth C., O'Dwyer T., Chambers T., Clarke L., Jebb D., Klopp J., Kavanagh D., Haslam K., Buckley P., Lemass K., Fitzpatrick F., Burns K., Cafferkey J., Richmond A., Foley M., Sanchez-Morgado J., Chalapati S., Pinnamaneni N., Crosbie C., Limbachiya D., Tinago W., Garcia Leon A. A., Miles S., Alalwan D., Negi R., Macken A., Feeney E., Kenny G., McCann K., Kelly N., Blair M., McCann R., Kenny C., O'Brion C., Waqas S., Savinelli S., Doran P., Bracken T., Varghese P., Lambert J. S., Cotter A., Muldoon E., Sheehan G., McGinty T., Lambert J., Green S., Leamy K., de Barra E., McConkey S., Kelly C., Horgan M., Sadlier C., Yousif O., O'Donnell J., Fitzgerald M., Petty-Saphon N., Cuddihy J., Fiore S., Fabiani C., Benedetti E., Di Mario G., Facchini M., Puzelli S., Calzoletti L., Fontana S., Venturi G., Fortuna C., Marsili G., Amendola A., Stuppia L., Savini G., Picerno A., Lopizzo T., Dell'Edera D., Minchella P., Greco F., Mauro M. V., Viglietto G., Atripaldi L., Limone A., D'Agaro P., Licastro D., Marcello A., Capobianchi M. R., Icardi G., Bruzzone B., Lillo F., Orsi A., Pariani E., Baldanti F., Gismondo M. R., Maggi F., Caruso A., Ceriotti F., Boniotti B., Bagnarelli P., Garofalo S., Scutella M., Pagani E., Collini L., Ghisetti V., Ru G., Chironna M., Parisi A., Rubino S., Serra C., Piras G., Coghe F., Vitale F., Tramuto F., Scalia G., Palermo C. I., Mancuso G., Di Gaudio F., Vullo S., Reale S., Cusi M. G., Rossolini G. M., Pistello M., Mencacci A., Camilloni B., Severini S., Di Benedetto M., Calogero T., Monne I., Biscaro V., COVID Study Groups, Funk T., Pharris A., Spiteri G., Bundle N., Melidou A., Carr M., Gonzalez G., Garcia-Leon A., Crispie F., O'Connor L., Murphy N., Mossong J., Vergison A., Wienecke-Baldacchino A.K., Abdelrahman T., Riccardo F., Stefanelli P., Di Martino A., Bella A., Lo Presti A., Casaca P., Moreno J., Borges V., Isidro J., Ferreira R., Gomes J.P., Dotsenko L., Suija H., Epstein J., Sadikova O., Sepp H., Ikonen N., Savolainen-Kopra C., Blomqvist S., Mottonen T., Helve O., Gomes-Dias J., Adlhoch C., Macori G., Russell L., Yandle Z., Bennett C., O'Byrne E., Murphy A., Tuite G., Conroy A., Duffy M., Morley U., Keoghan B., Ford I., Kennedy M., McDonnell S., Flynn A., Clarke A., Crowley A., Martin C., Kelly E., Foxton J., Hare D., Dunford L., Connell J., Moran J., Dean J., Fanning S., Rajan L., De Gascun C., Kenny J., Cotter P., Walsh C., Lawton E., Fitzpatrick A., Mullins E., Della Bartola M., McCabe M., Stapleton P., Meaney C., Fanning L., Prentice M., MacSharry J., Dempsey C., Mallon P., Leon A., Chaturvedi A., Coughlan S., McAndrew G., Reddington K., Walsh F., Fitzpatrick D., Smyth C., O'Dwyer T., Chambers T., Clarke L., Jebb D., Klopp J., Kavanagh D., Haslam K., Buckley P., Lemass K., Fitzpatrick F., Burns K., Cafferkey J., Richmond A., Foley M., Sanchez-Morgado J., Chalapati S., Pinnamaneni N., Crosbie C., Limbachiya D., Tinago W., Garcia Leon A.A., Miles S., Alalwan D., Negi R., Macken A., Feeney E., Kenny G., McCann K., Kelly N., Blair M., McCann R., Kenny C., O'Brion C., Waqas S., Savinelli S., Doran P., Bracken T., Varghese P., Lambert J.S., Cotter A., Muldoon E., Sheehan G., McGinty T., Lambert J., Green S., Leamy K., de Barra E., McConkey S., Kelly C., Horgan M., Sadlier C., Yousif O., O'Donnell J., Fitzgerald M., Petty-Saphon N., Cuddihy J., Fiore S., Fabiani C., Benedetti E., Di Mario G., Facchini M., Puzelli S., Calzoletti L., Fontana S., Venturi G., Fortuna C., Marsili G., Amendola A., Stuppia L., Savini G., Picerno A., Lopizzo T., Dell'Edera D., Minchella P., Greco F., Mauro M.V., Viglietto G., Atripaldi L., Limone A., D'Agaro P., Licastro D., Marcello A., Capobianchi M.R., Icardi G., Bruzzone B., Lillo F., Orsi A., Pariani E., Baldanti F., Gismondo M.R., Maggi F., Caruso A., Ceriotti F., Boniotti B., Bagnarelli P., Garofalo S., Scutella M., Pagani E., Collini L., Ghisetti V., Ru G., Chironna M., Parisi A., Rubino S., Serra C., Piras G., Coghe F., Vitale F., Tramuto F., Scalia G., Palermo C.I., Mancuso G., Di Gaudio F., Vullo S., Reale S., Cusi M.G., Rossolini G.M., Pistello M., Mencacci A., Camilloni B., Severini S., Di Benedetto M., Calogero T., Monne I., Biscaro V., and COVID Study Groups

Subjects
Infecções Respiratórias, 2019-20 coronavirus outbreak, medicine.medical_specialty, Coronavirus disease 2019 (COVID-19), Critical Care, Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), variants of concern, Settore MED/42 - Igiene Generale E Applicata, 03 medical and health sciences, 0302 clinical medicine, Virology, Internal medicine, Medicine, Humans, Intensive care admission, 030212 general & internal medicine, COVID-19, Europe, SARS-CoV-2, surveillance, Surveillance, business.industry, 030503 health policy & services, Public Health, Environmental and Occupational Health, Odds ratio, Confidence interval, Variants of Concern, COVID-19, Europe, SARS-CoV-2, surveillance, variants of concern, 0305 other medical science, business, Rapid Communication, Human
Abstract

COVID study groups - PORTUGAL: Portuguese Laboratory Network for the Diagnosis of COVID-19 and Public Health Department of the Health Administrative Regions, Physicians that provided data and samples from suspected cases and SARS-CoV-2 genetic characterization. INSA laboratory team for the diagnosis of SARS-CoV-2. Algarve Biomedical Center and Unilabs. We compared 19,207 cases of SARS-CoV-2 variant B.1.1.7/S gene target failure (SGTF), 436 B.1.351 and 352 P.1 to non-variant cases reported by seven European countries. COVID-19 cases with these variants had significantly higher adjusted odds ratios for hospitalisation (B.1.1.7/SGTF: 1.7, 95% confidence interval (CI): 1.0-2.9; B.1.351: 3.6, 95% CI: 2.1-6.2; P.1: 2.6, 95% CI: 1.4-4.8) and B.1.1.7/SGTF and P.1 cases also for intensive care admission (B.1.1.7/SGTF: 2.3, 95% CI: 1.4-3.5; P.1: 2.2, 95% CI: 1.7-2.8). ECDC internal funds. The ICSC and the AIID Cohort are supported by Science Foundation Ireland under the Science Foundation Ireland, Enterprise Ireland, IDA Ireland COVID-19 Rapid Response Funding Call (Grant number: COVID-RRC 20/COV/0103 and COVID-RRC 20/COV/0305). info:eu-repo/semantics/publishedVersion

Published
2021

14. Determinants of SARS-CoV-2 infection in Italian healthcare workers: a multicenter study

Author

Boffetta P., Violante F., Durando P., De Palma G., Pira E., Vimercati L., Cristaudo A., Icardi G., Sala E., Coggiola M., Tafuri S., Gattini V., Apostoli P., Spatari G., De Maria L., Caputi A., Sponselli S., Mastrippolito C., Zunarelli C., Di Felice G., Visci G., Albini E., Sansone E., Tomasi C., Bisioli A., Cipriani L., De Bellis A., Tiraboschi M. M., Paraggio E., Rubino S., Capuzzi M., Dini G., Bruzzone B., Debarbieri N., Montecucco A., Orsi A., Rahmani A., Ricucci V., Guglielmi G., Fiorentino L., Brilli C., Godono A., Declementi M., Mansour I., Milanesio N., Garzaro G., Scarmozzino A., Gullino A., Boffetta P., Violante F., Durando P., De Palma G., Pira E., Vimercati L., Cristaudo A., Icardi G., Sala E., Coggiola M., Tafuri S., Gattini V., Apostoli P., Spatari G., De Maria L., Caputi A., Sponselli S., Mastrippolito C., Zunarelli C., Di Felice G., Visci G., Albini E., Sansone E., Tomasi C., Bisioli A., Cipriani L., De Bellis A., Tiraboschi M.M., Paraggio E., Rubino S., Capuzzi M., Dini G., Bruzzone B., Debarbieri N., Montecucco A., Orsi A., Rahmani A., Ricucci V., Guglielmi G., Fiorentino L., Brilli C., Godono A., Declementi M., Mansour I., Milanesio N., Garzaro G., Scarmozzino A., and Gullino A.

Subjects
Adult, Male, medicine.medical_specialty, Science, Health Personnel, 030501 epidemiology, Logistic regression, Lower risk, Article, Malaise, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, COVID-19, Female, Humans, Italy, Mass Screening, Middle Aged, Occupational Diseases, SARS-CoV-2, Epidemiology, Medicine, 030212 general & internal medicine, Risk factor, Personal protective equipment, Mass screening, Multidisciplinary, business.industry, Risk of infection, Odds ratio, Confidence interval, Occupational Disease, Risk factors, Emergency medicine, medicine.symptom, 0305 other medical science, business, Health occupations, Human
Abstract

BackgroundHealthcare workers (HCW) are at increased risk of being infected with SARS-CoV-2, yet limited information is available on risk factors of infection.MethodsWe pooled data on occupational surveillance of 10,654 HCW who were tested for SARS-CoV-2 infection in six Italian centers. Information was available on demographics, job title, department of employment, source of exposure, use of personal protective equipment (PPE), and COVID-19-related symptoms. We fitted multivariable logistic regression models to calculate odds ratios (OR) and 95% confidence intervals (CI).FindingsThe prevalence of infection varied across centers and ranged from 3.0% to 22.0%, being strongly correlated with that of the respective areas. Women were at lower risk of infection compared to men. Fever, cough, dyspnea and malaise were the symptoms most strongly associated with infection, together with anosmia and ageusia. No differences in the risk of infection were detected between job titles, or working in a COVID-19 designated department. Reported contact with a patient inside or outside the workplace was a risk factor. Use of a mask was strongly protective against risk of infection as was use of gloves. The use of a mask by the source of exposure (patient or colleague) had an independent effect in reducing infection risk.

Published
2021

15. A Comparison of Hepatitis B Seroepidemiology in Ten European Countries

Author

Nardone, A., Anastassopoulou, C. G., Theeten, H., Kriz, B., Davidkin, I., Thierfelder, W., O'Flanagan, D., Bruzzone, B., Mossong, J., Boot, H. J., Butur, D., Slačiková, M., Panait, M. L. C., Hellenbrand, W., de Melker, H., Sobotová, Z., Icardi, G., Andrews, N., Pebody, R. G., van Damme, P., Kafatos, G., Miller, E., and Hatzakis, A.

Published
2009
Full Text
View/download PDF

16. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies

Author

Sormani M. P., Schiavetti I., Carmisciano L., Inglese M., Laroni A., Lapucci C., Uccelli A., Da Rin G., Serrati C., Gandoglia I., Tassinari T., Perego G., Brichetto G., Gazzola P., Mannironi A., Stromillo M. L., Cordioli C., Landi D., Clerico M., Signoriello E., Frau J., Ferro M. T., Di Sapio A., Pasquali L., Ulivelli M., Marinelli F., Callari G., Iodice R., Liberatore G., Caleri F., Repice A. M., Cordera S., Battaglia M. A., Salvetti M., Franciotta D., Maglione A., Signori A., Iovino A., Nicoletti C. G., Mancinelli C. R., Bezzini D., Carmagnini D., Brogi D., Orazio E. N., Cocco E., Nako E., Assandri E., Baldi F., Ansaldi F., Bovis F., Siciliano G., Cola G., Lus G., Icardi G., bellucci G., Rin G. D., Marfia G. A., Vazzoler G., Trivelli G., Maietta I., Sticchi L., Lorefice L., Ruggiero L., Manzino M., Bragadin M. M., Buscarinu M. C., Gagliardi M., Rilla M. T., Ponzano M., Fronza M., Sette M. D., Scialabba M., Bedognetti M., De Rossi N., De Stefano N., Bigi R., Dubbioso R., Renie R., Fabbri S., Rasia S., Rolla S., Platzgummer S., Carlini V., Sormani, M. P., Schiavetti, I., Carmisciano, L., Inglese, M., Laroni, A., Lapucci, C., Uccelli, A., Da Rin, G., Serrati, C., Gandoglia, I., Tassinari, T., Perego, G., Brichetto, G., Gazzola, P., Mannironi, A., Stromillo, M. L., Cordioli, C., Landi, D., Clerico, M., Signoriello, E., Frau, J., Ferro, M. T., Di Sapio, A., Pasquali, L., Ulivelli, M., Marinelli, F., Callari, G., Iodice, R., Liberatore, G., Caleri, F., Repice, A. M., Cordera, S., Battaglia, M. A., Salvetti, M., Franciotta, D., Maglione, A., Signori, A., Iovino, A., Nicoletti, C. G., Mancinelli, C. R., Bezzini, D., Carmagnini, D., Brogi, D., Orazio, E. N., Cocco, E., Nako, E., Assandri, E., Baldi, F., Ansaldi, F., Bovis, F., Siciliano, G., Cola, G., Lus, G., Icardi, G., Bellucci, G., Rin, G. D., Marfia, G. A., Vazzoler, G., Trivelli, G., Maietta, I., Sticchi, L., Lorefice, L., Ruggiero, L., Manzino, M., Bragadin, M. M., Buscarinu, M. C., Gagliardi, M., Rilla, M. T., Ponzano, M., Fronza, M., Sette, M. D., Scialabba, M., Bedognetti, M., De Rossi, N., De Stefano, N., Bigi, R., Dubbioso, R., Renie, R., Fabbri, S., Rasia, S., Rolla, S., Platzgummer, S., and Carlini, V.

Subjects
Oncology, Male, Medicine (General), COVID-19 Vaccine, Immunosuppressive Agent, Multiple Sclerosi, Monoclonal, Prospective Studies, Humanized, biology, Coronavirus, Immunomodulatory therapies, Multiple sclerosis, General Medicine, Middle Aged, 2019-nCoV Vaccine mRNA-1273, Adult, Antibodies, Monoclonal, Humanized, Antibody Formation, BNT162 Vaccine, COVID-19, COVID-19 Vaccines, Cladribine, Female, Fingolimod Hydrochloride, Humans, Immunosuppressive Agents, Italy, Multiple Sclerosis, Rituximab, Treatment Outcome, Fingolimod, Vaccination, Immunomodulatory therapie, Medicine, Antibody, medicine.drug, Human, medicine.medical_specialty, Coronaviru, Context (language use), Settore MED/26, Article, General Biochemistry, Genetics and Molecular Biology, Antibodies, R5-920, Antigen, Internal medicine, medicine, business.industry, medicine.disease, Prospective Studie, biology.protein, Ocrelizumab, business
Abstract

Background: In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects immune response to antigens. Therefore, post-vaccination serological assessments are needed to evaluate the effect of the vaccine on SARS-CoV-2 antibody response. Methods: We designed a prospective multicenter cohort study enrolling pwMS who were scheduled for SARS-Cov-2 vaccination with mRNA vaccines (BNT162b2, Pfizer/BioNTech,Inc or mRNA-1273, Moderna Tx,Inc). A blood collection before the first vaccine dose and 4 weeks after the second dose was planned, with a centralized serological assessment (electrochemiluminescence immunoassay, ECLIA, Roche-Diagnostics). The log-transform of the antibody levels was analyzed by multivariable linear regression. Findings: 780 pwMS (76% BNT162b2 and 24% mRNA-1273) had pre- and 4-week post-vaccination blood assessments. 87 (11·2%) were untreated, 154 (19·7%) on ocrelizumab, 25 (3·2%) on rituximab, 85 (10·9%) on fingolimod, 25 (3·2%) on cladribine and 404 (51·7%) on other DMTs. 677 patients (86·8%) had detectable post-vaccination SARS-CoV-2 antibodies. At multivariable analysis, the antibody levels of patients on ocrelizumab (201-fold decrease (95%CI=128–317), p < 0·001), fingolimod (26-fold decrease (95%CI=16–42), p < 0·001) and rituximab (20-fold decrease (95%CI=10–43), p < 0·001) were significantly reduced as compared to untreated patients. Vaccination with mRNA-1273 resulted in a systematically 3·25-fold higher antibody level (95%CI=2·46–4·27) than with the BNT162b2 vaccine (p < 0·001). The antibody levels on anti-CD20 therapies correlated to the time since last infusion, and rituximab had longer intervals (mean=386 days) than ocrelizumab patients (mean=129 days). Interpretation: In pwMS, anti-CD20 treatment and fingolimod led to a reduced humoral response to mRNA-based SARS-CoV-2 vaccines. As mRNA-1273 elicits 3·25-higher antibody levels than BNT162b2, this vaccine may be preferentially considered for patients under anti-CD20 treatment or fingolimod. Combining our data with those on the cellular immune response to vaccines, and including clinical follow-up, will contribute to better define the most appropriate SARS-CoV-2 vaccine strategies in the context of DMTs and MS. Funding: FISM[2021/Special-Multi/001]; Italian Ministry of Health‘Progetto Z844A 5 × 1000′.

Published
2021

17. Vaccination coverage in healthcare workers: a multicenter cross-sectional study in Italy

Author

Genovese C., Picerno I. A. M., Trimarchi G., Cannavo G., Egitto G., Cosenza B., Merlina V., Icardi G., Panatto D., Amicizia D., Orsi A., Colosio C., Marsili C., Lari C., Palamara M. A. R., Vitale F., Casuccio A., Costantino C., Azara A., Castiglia P., Bianco A., Curra A., Gabutti G., Stefanati A., Sandri F., Florescu C., Marranzano M., Giorgianni G., Fiore V., Platania A., Torre I., Cappuccio A., Guillari A., Fabiani L., Giuliani A. R., Appetiti A., La Fauci V., Squeri A., Ragusa R., Squeri R., Genovese, C., Picerno, I. A. M., Trimarchi, G., Cannavo, G., Egitto, G., Cosenza, B., Merlina, V., Icardi, G., Panatto, D., Amicizia, D., Orsi, A., Colosio, C., Marsili, C., Lari, C., Palamara, M. A. R., Vitale, F., Casuccio, A., Costantino, C., Azara, A., Castiglia, P., Bianco, A., Curra, A., Gabutti, G., Stefanati, A., Sandri, F., Florescu, C., Marranzano, M., Giorgianni, G., Fiore, V., Platania, A., Torre, I., Cappuccio, Antonella, Guillari, A., Fabiani, L., Giuliani, A. R., Appetiti, A., La Fauci, V., Squeri, A., Ragusa, R., Squeri, R., Genovese C., Picerno I.A.M., Trimarchi G., Cannavo G., Egitto G., Cosenza B., Merlina V., Icardi G., Panatto D., Amicizia D., Orsi A., Colosio C., Marsili C., Lari C., Palamara M.A.R., Vitale F., Casuccio A., Costantino C., Azara A., Castiglia P., Bianco A., Curra A., Gabutti G., Stefanati A., Sandri F., Florescu C., Marranzano M., Giorgianni G., Fiore V., Platania A., Torre I., Cappuccio A., Guillari A., Fabiani L., Giuliani A.R., Appetiti A., La Fauci V., Squeri A., Ragusa R., and Squeri R.

Subjects
Adult, Male, 0303 health sciences, Vaccines, 030306 microbiology, Health Personnel, education, Nurses, Middle Aged, Infectious Disease Transmission, Professional-to-Patient, NO, 03 medical and health sciences, Healthcare workers, Vaccination coverage, Cross-Sectional Studies, Healthcare workers, Vaccination coverage, Vaccines, Italy, Physicians, Healthcare worker, Humans, Original Article, Female
Abstract

Introduction In recent years, a phenomenon known as "vaccine hesitancy" has spread throughout the world, even among health workers, determining a reduction in vaccination coverage (VC). A study aimed at evaluating VC among healthcare workers (HCWs) in 10 Italian cities (L'Aquila, Genoa, Milan, Palermo, Sassari, Catanzaro, Ferrara, Catania, Naples, Messina) was performed. Materials and methods Annex 3 of the Presidential Decree n. 445 of 28 December 2000 was used to collect information on the vaccination status of HCWs. The mean and standard deviation (SD) were calculated with regard to the quantitative variable (age), while absolute and relative frequencies were obtained for categorical data (sex, professional profile, working sector, vaccination status). The connection between VC and the categorical variables was evaluated by chi-square method (statistical significance at p, Journal of Preventive Medicine and Hygiene, Vol 60, No 1 (2019): 2019601

Published
2019

18. Immunogénicité et tolérance d’un vaccin grippal quadrivalent à haute dose par rapport à un vaccin grippal quadrivalent à dose standard chez des sujets de 60 ans et plus : un essai randomisé de phase III

Author

Pepin, S., primary, Nicolas, J., additional, Szymanski, H., additional, Leroux-roels, I., additional, Schaum, T., additional, Bonten, M., additional, Icardi, G., additional, Donazzolo, Y., additional, Launay, O., additional, and de Bruijn, I., additional

Published
2021
Full Text
View/download PDF

19. Health Communication in COVID-19 Era: Experiences from the Italian VaccinarSì Network Websites

Author

Arghittu, A, Dettori, M, Dempsey, E, Deiana, G, Angelini, C, Bechini, A, Bertoni, C, Boccalini, S, Bonanni, P, Cinquetti, S, Chiesi, F, Chironna, M, Costantino, C, Ferro, A, Fiacchini, D, Icardi, G, Poscia, A, Russo, F, Siddu, A, Spadea, A, Sticchi, L, Triassi, M, Vitale, F, and Castiglia, P.

Subjects
health communication, e-health, vaccine hesitancy, website, VaccinarSì network
Published
2021

20. Prevention Italy 2021 - An update of the 2018 Consensus document and recommendations for the prevention of cardiovascular disease in Italy

Author

Battistoni, A., Gallo, G., Aragona, C. O., Barchiesi, F., Basolo, A., Bellone, S., Bellotti, P., Bertolotti, M., Bianco, A., Biffi, A., Borghi, C., Cicero, A. F. G., Consoli, A., Corsini, A., Desideri, G., Di Giacinto, B., Fernando, F., Ferri, C., Galiuto, L., Grassi, D., Grassi, G., Icardi, G., Indolfi, C., Lodi, E., Modena, M. G., Muiesan, M. L., Nati, G., Orsi, A., Palermi, S., Parati, G., Passantino, A., Patelli, A., Pelliccia, A., Pengo, M., Filardi, P. P., Perseghin, G., Pirro, M., Pontremoli, R., Rengo, G., Ricotti, R., Rizzoni, D., Rocca, B., Rotella, C., Rubattu, S., Salvetti, G., Sciacqua, A., Serdoz, A., Sirico, F., Squeo, M. R., Tocci, G., Trimarco, B., Vigili de Kreutzenberg, S., Volpe, R., and Volpe, M.

Subjects
Consensus, Italy, Humans, Risk Assessment, Risk Factors, Cardiovascular Diseases
Published
2021

21. A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study

Author

Vandermeulen, C, Leroux-Roels, I, Vandeleur, J, Staniscia, T, Girard, G, Ferguson, M, Icardi, G, Schwarz, TF, Neville, AM, Nolan, T, Cinquetti, S, Akhund, T, Van Huyneghem, S, Aggravi, M, Kunnel, B, de Wergifosse, B, Di Domenico, GF, Costantini, M, Singh, PV, Fragapane, E, Lattanzi, M, Pellegrini, M, Vandermeulen, C, Leroux-Roels, I, Vandeleur, J, Staniscia, T, Girard, G, Ferguson, M, Icardi, G, Schwarz, TF, Neville, AM, Nolan, T, Cinquetti, S, Akhund, T, Van Huyneghem, S, Aggravi, M, Kunnel, B, de Wergifosse, B, Di Domenico, GF, Costantini, M, Singh, PV, Fragapane, E, Lattanzi, M, and Pellegrini, M

Abstract

BACKGROUND: The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilised MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid formulation in a single vial has been developed to further improve the vaccine presentation. Since the MenA structure is subject to hydrolytic degradation, this study was conducted to compare the immunogenicity and safety of the investigational MenACWY-CRM liquid vaccine with the licensed vaccine. METHODS: In this multicentre, randomised, controlled, observer-blind, phase 2b study, 979 healthy adults were administered a single dose of MenACWY-CRM liquid presentation or the currently licensed MenACWY-CRM vaccine. MenA free saccharide generation was accelerated to approximately 30% in the liquid presentation and MenA polysaccharide O-acetylation was reduced to approximately 40%, according to a controlled procedure. Immunological non-inferiority of the MenACWY-CRM liquid to the licensed vaccine, as measured by human serum bactericidal assay (hSBA) geometric mean titres (GMTs) against MenA 1 month post-vaccination, was the primary study objective. Safety assessment was among the secondary objectives. RESULTS: Immune responses against each serogroup were similar between the two vaccine groups and was non-inferior for MenA. Adjusted hSBA GMTs for MenA were 185.16 and 211.33 for the MenACWY-CRM liquid presentation and currently licensed vaccine presentation, respectively. The between-group ratio of hSBA GMTs for MenA was 0.88, with a two-sided 95% confidence interval lower limit of 0.64, greater than the prespecified non-inferiority margin of 0.5, thus meeting the primary study objective. Both vaccines were well tolerated. No serious adverse events were considered related to vaccination. CONCLUSIONS: The levels of MenA free saccharide and polysaccharide O-acetylation did not affect the immunogenicity of the fully liquid presentation, which was demonstrated to be non-inf

Published
2021

22. Prevention Italy 2021 - An update of the 2018 Consensus document and recommendations for the prevention of cardiovascular disease in Italy [Prevenzione Italia 2021 Un update del Documento di consenso e raccomandazioni per la prevenzione cardiovascolare in Italia]

Author

Battistoni, A, Gallo, G, Aragona, C, Barchiesi, F, Basolo, A, Bellone, S, Bellotti, P, Bertolotti, M, Bianco, A, Biffi, A, Borghi, C, Cicero, A, Consoli, A, Corsini, A, Desideri, G, Di Giacinto, B, Fernando, F, Ferri, C, Galiuto, L, Grassi, D, Grassi, G, Icardi, G, Indolfi, C, Lodi, E, Modena, M, Muiesan, M, Nati, G, Orsi, A, Palermi, S, Parati, G, Passantino, A, Patelli, A, Pelliccia, A, Pengo, M, Filardi, P, Perseghin, G, Pirro, M, Pontremoli, R, Rengo, G, Ricotti, R, Rizzoni, D, Rocca, B, Rotella, C, Rubattu, S, Salvetti, G, Sciacqua, A, Serdoz, A, Sirico, F, Squeo, M, Tocci, G, Trimarco, B, Vigili de Kreutzenberg, S, Volpe, R, Volpe, M, Battistoni, Allegra, Gallo, Giovanna, Aragona, Caterina Oriana, Barchiesi, Fabio, Basolo, Alessio, Bellone, Simonetta, Bellotti, Paolo, Bertolotti, Marco, Bianco, Andrea, Biffi, Alessandro, Borghi, Claudio, Cicero, Arrigo Francesco Giuseppe, Consoli, Agostino, Corsini, Alberto, Desideri, Giovambattista, Di Giacinto, Barbara, Fernando, Fredrik, Ferri, Claudio, Galiuto, Leonarda, Grassi, Davide, Grassi, Guido, Icardi, Giancarlo, Indolfi, Ciro, Lodi, Elisa, Modena, Maria Grazia, Muiesan, Maria Lorenza, Nati, Giulio, Orsi, Andrea, Palermi, Stefano, Parati, Gianfranco, Passantino, Andrea, Patelli, Alessandra, Pelliccia, Antonio, Pengo, Martino, Filardi, Pasquale Perrone, Perseghin, Gianluca, Pirro, Matteo, Pontremoli, Roberto, Rengo, Giuseppe, Ricotti, Roberta, Rizzoni, Damiano, Rocca, Bianca, Rotella, Carlo, Rubattu, Speranza, Salvetti, Guido, Sciacqua, Angela, Serdoz, Andrea, Sirico, Felice, Squeo, Maria Rosaria, Tocci, Giuliano, Trimarco, Bruno, Vigili de Kreutzenberg, Saula, Volpe, Roberto, Volpe, Massimo, Battistoni, A, Gallo, G, Aragona, C, Barchiesi, F, Basolo, A, Bellone, S, Bellotti, P, Bertolotti, M, Bianco, A, Biffi, A, Borghi, C, Cicero, A, Consoli, A, Corsini, A, Desideri, G, Di Giacinto, B, Fernando, F, Ferri, C, Galiuto, L, Grassi, D, Grassi, G, Icardi, G, Indolfi, C, Lodi, E, Modena, M, Muiesan, M, Nati, G, Orsi, A, Palermi, S, Parati, G, Passantino, A, Patelli, A, Pelliccia, A, Pengo, M, Filardi, P, Perseghin, G, Pirro, M, Pontremoli, R, Rengo, G, Ricotti, R, Rizzoni, D, Rocca, B, Rotella, C, Rubattu, S, Salvetti, G, Sciacqua, A, Serdoz, A, Sirico, F, Squeo, M, Tocci, G, Trimarco, B, Vigili de Kreutzenberg, S, Volpe, R, Volpe, M, Battistoni, Allegra, Gallo, Giovanna, Aragona, Caterina Oriana, Barchiesi, Fabio, Basolo, Alessio, Bellone, Simonetta, Bellotti, Paolo, Bertolotti, Marco, Bianco, Andrea, Biffi, Alessandro, Borghi, Claudio, Cicero, Arrigo Francesco Giuseppe, Consoli, Agostino, Corsini, Alberto, Desideri, Giovambattista, Di Giacinto, Barbara, Fernando, Fredrik, Ferri, Claudio, Galiuto, Leonarda, Grassi, Davide, Grassi, Guido, Icardi, Giancarlo, Indolfi, Ciro, Lodi, Elisa, Modena, Maria Grazia, Muiesan, Maria Lorenza, Nati, Giulio, Orsi, Andrea, Palermi, Stefano, Parati, Gianfranco, Passantino, Andrea, Patelli, Alessandra, Pelliccia, Antonio, Pengo, Martino, Filardi, Pasquale Perrone, Perseghin, Gianluca, Pirro, Matteo, Pontremoli, Roberto, Rengo, Giuseppe, Ricotti, Roberta, Rizzoni, Damiano, Rocca, Bianca, Rotella, Carlo, Rubattu, Speranza, Salvetti, Guido, Sciacqua, Angela, Serdoz, Andrea, Sirico, Felice, Squeo, Maria Rosaria, Tocci, Giuliano, Trimarco, Bruno, Vigili de Kreutzenberg, Saula, Volpe, Roberto, and Volpe, Massimo

Published
2021

23. Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018 [Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018]

Author

Volpe, M, Tocci, G, Accettura, D, Battistoni, A, Costanzo, G, Rubattu, S, Volpe, R, Bellone, S, Ricotti, R, Bellotti, P, Bertolotti, M, Modena, M, Borghi, C, Casasco, M, Rizzoni, D, Consoli, A, Coppini, R, Galanti, G, Lombardi, N, Modesti, P, Mugelli, A, Rotella, C, Corsini, A, Parati, G, Perseghin, G, Desideri, G, Ferri, C, Giada, F, Icardi, G, Orsi, A, Monti, G, Pedretti, R, Pirro, M, Salvetti, G, Sarto, P, Tassinari, F, Trimarco, B, de Kreutzenberg, S, Volpe M., Tocci G., Accettura D., Battistoni A., Costanzo G., Rubattu S., Volpe R., Bellone S., Ricotti R., Bellotti P., Bertolotti M., Modena M. G., Borghi C., Casasco M., Rizzoni D., Consoli A., Coppini R., Galanti G., Lombardi N., Modesti P. A., Mugelli A., Rotella C., Corsini A., Parati G., Perseghin G., Desideri G., Ferri C., Giada F., Icardi G., Orsi A., Monti G., Pedretti R. F. E., Pirro M., Salvetti G., Sarto P., Tassinari F., Trimarco B., de Kreutzenberg S. V., Volpe, M, Tocci, G, Accettura, D, Battistoni, A, Costanzo, G, Rubattu, S, Volpe, R, Bellone, S, Ricotti, R, Bellotti, P, Bertolotti, M, Modena, M, Borghi, C, Casasco, M, Rizzoni, D, Consoli, A, Coppini, R, Galanti, G, Lombardi, N, Modesti, P, Mugelli, A, Rotella, C, Corsini, A, Parati, G, Perseghin, G, Desideri, G, Ferri, C, Giada, F, Icardi, G, Orsi, A, Monti, G, Pedretti, R, Pirro, M, Salvetti, G, Sarto, P, Tassinari, F, Trimarco, B, de Kreutzenberg, S, Volpe M., Tocci G., Accettura D., Battistoni A., Costanzo G., Rubattu S., Volpe R., Bellone S., Ricotti R., Bellotti P., Bertolotti M., Modena M. G., Borghi C., Casasco M., Rizzoni D., Consoli A., Coppini R., Galanti G., Lombardi N., Modesti P. A., Mugelli A., Rotella C., Corsini A., Parati G., Perseghin G., Desideri G., Ferri C., Giada F., Icardi G., Orsi A., Monti G., Pedretti R. F. E., Pirro M., Salvetti G., Sarto P., Tassinari F., Trimarco B., and de Kreutzenberg S. V.

Abstract

Cardiovascular prevention represents a cornerstone of modern strategies to reduce the burden of cardiovascular disease. It is of key importance to prevent cardiovascular diseases and associated events, not only to reduce morbidity and mortality, but also to increase the years of wellness in the aging population and to make the growing socio-economic burden imposed by cardiovascular events more sustainable. The current approach to prevention is based on an integrated use of effective lifestyle measures and, whenever appropriate, of antihypertensive and antidiabetic drugs, lipid-lowering agents and antiplatelet drugs. Given that population characteristics, in terms of ethnicity, demography and lifestyle habits, and healthcare system organizations differ among countries, international guidelines are not always applicable to specific countries and, often, are difficult to translate into daily clinical practice. In order to afford the specific features of Italy, 10 Scientific Societies and Research Institutions, mostly involved in preventive strategies, contributed to the present Italian consensus document, which includes brief, practical recommendations to support the preventive actions within the physician community and the general practice setting.

Published
2018

26. Demographic and Socio-economic Determinants of Poor HIV-risk Perception at First HIV Diagnosis: Analysis of the HIV Surveillance Data, Italy 2010-2016

Author

Dorrucci, M., Regine, V., Pezzotti, P., Mammone, A., Girardi, E., Suligoi, B, Icardi, G, and Lai, P.

Subjects
Adult, Male, Adolescent, Social Determinants of Health, Epidemiology, Sexual Behavior, HIV Infections, Risk Assessment, Young Adult, Odds Ratio, Humans, Substance Abuse, Intravenous, Aged, HIV, Risk-perception, Aged, 80 and over, Motivation, Age Factors, AIDS Serodiagnosis, Middle Aged, Patient Acceptance of Health Care, CD4 Lymphocyte Count, Italy, Population Surveillance, Educational Status, Female, Attitude to Health
Abstract

HIV infections in Italy has not undergone a substantial decline over recent years. For this reason, we analysed risk-factors and socio-economic indicators of HIV-risk perception in HIV surveillance data.An observational study was conducted and HIV-risk perception was estimated on the basis of reasons for undergoing testing. Ordinal logistic models were applied with three groups of response corresponding to three ordered levels of HIV-risk perception.The study included 18 055 individuals: 27% with low, 40% moderate and 33% with high perception. A low risk perception was estimated in both areas, least deprived and highly deprived [Adjusted Odds Ratio (AOR) = 1.58, CI: 1.14-2.18 and AOR = 2.33, CI: 1.39-3.90]; for heterosexuals (AOR = 1.96, CI: 1.83-2.11), Injecting Drug Users (IDU) (AOR =1.82, CI: 1.59-2.08), low education (AOR = 1.74. CI: 1.20-2.54), age40 years (AOR = 1.59, CI: 1.50-1.69), males (AOR = 1.30, CI: 1.20-1.40).In Italy there is a high percentage of HIV-infected people with poor HIV-risk perception. Poorer HIV-risk perception was associated with both, least and high deprivation, low education, older age, male gender, heterosexual and IDU groups. Our results could be relevant to address targeted HIV testing policies at both local and national levels.

Published
2020

27. The fight to end tuberculosis: A global challenge in strong partnership

Author

Martini, M., Barberis, I., Gazzaniga, V., and Icardi, G.

Subjects
International Cooperation, Global Health, Global challenge, Tuberculosis, global challenges, partnership, Editorial, Cost of Illness, Tuberculosis, Multidrug-Resistant, Humans, Partnership, Disease Eradication, Epidemics
Abstract

Journal of Preventive Medicine and Hygiene, Vol. 61 No. 1s1 (2020): Tuberculosis. The Never Ending Story: past, present and Future Challeng (Parte I)

Published
2020

29. A Bivalent Meningococcal B Vaccine in Adolescents and Young Adults

Author

Ostergaard, L., Vesikari, T., Absalon, J., Beeslaar, J., Ward, B. J., Senders, S., Eiden, J. J., Jansen, K. U., Anderson, A. S., York, L. J., Jones, T. R., Harris, S. L., O'Neill, R., Radley, D., Maansson, R., Pregaldien, J. -L., Ginis, J., Staerke, N. B., Perez, J. L., Belle-Isle, J, Elfassi, E, Fredette, P, Garfield, H, Girard, G, Lachance, P, Adamkova, E, Bartonova, E, Drazan, D, Dvorakova, J, Kosina, P, Kyjonkova, A, Ruzkova, R, Vitousova, E, Ahonen, A, Forsten, A, Karppa, T, Kokko, S, Lagerstrom-Tirri, Pm, Simila, Jk, Adelt, T, Behre, U, Schwarz, Tf, Castiglia, P, Esposito, S, Ferrera, G, Icardi, G, Brzostek, J, Hasiec, B, Konior, R, Pejcz, J, Szymanski, H, Witor, A, Faust, Sn, Finn, Ah, Heath, Pt, Pollard, Aj, Altamirano, Dd, Ashley CT Jr, Bader, Gf, Bauer GH Jr, Block SL Jr, Brandon, Dm, Davis, Mg, Devalle, O, Egelhof, Rh, Essink, Bj, Fouch, Bb, Fox, Bp, Franklin, Er, Garscadden, Ag, Goswami, Up, Gregory, Dm, Helman, Ll, Houchin, Vg, Howard, Ce, Johnson, Ad, Johnston WH Jr, Jordan, Ca, Kimmel, Ma, Klein, Tr, Krilov, Lr, Labarbera, Ap, Labuda JM II, Latiolais, Tg, Lello, Lg, Lewis, Dh, Ley, Ja, London, Al, Martin, Ms, Mcguire, Mr, Mosteller, Vc, Naccarato, Tr, Nassim, Cg, Rey, Mr, Robbins, Ra, Rouse, Kg, Schear, Mj, Senders, Sd, Shepard, Js, Simpson, Mw, Slandzicki, Aj, Slechta, Sb, Tetrick, Ll, Varman, M, Wadsworth LT III, Ware, Db, White, Jh, Wisman PP Jr, Blouin, F, Dionne, M, Dzongowski, P, Heaton, Kj, Langley, Jm, O'Mahony, Mfj, Powell, Cn, Ward, Bj, Ostergaard, Lj, Haapaniemi, Tl, Paassilta, M, Volanen, Ik, Lepich, T, Smukalska, E, Tarczon, I, Tetiurka, Bm, Domingo, Jd, Morato, Av, Riera, Mt, Sanchez, Ca, Torrell, Jmr, Blumenau, J, Campbell, Ng, Cervantes, Ja, Douglas, Wg, Ensz, Dj, Ervin, Je, Fiel, Tc, Fragoso, Vg, Fried, Dl, Gleason, Gp, Green, Sl, Haggag, Az, Johnson, Ct, Khaira, Rs, Kirstein, Jl, Kravitz, Ae, Lederman, Sn, Marcadis, I, Miller, Ve, Moretti, Jm, Pragalos, Aa, Puopolo, Ad, Rubino, J, Seiden, Dj, Sharp, Sc, Sheldon, Ea, Shockey, Gr, Smith, Wb, Stringer, Jc, Strout, Cb, Studdard, He, and Tresser, Njl.

Subjects
Male, 0301 basic medicine, Clinical Trial, Phase III, Hepatitis A vaccine, Neisseria meningitidis, Serogroup B, Neisseria meningitidis, medicine.disease_cause, bacterial protein, Group B, 0302 clinical medicine, Single-Blind Method, 030212 general & internal medicine, Child, Phylogeny, biology, Immunogenicity, Bacterial, General Medicine, hepatitis A vaccine, Meningococcus vaccine, bacterial antigen, bacterium antibody, factor H-binding protein, Neisseria meningitidis, Antibodies, Bacterial, Intention to Treat Analysis, Multicenter Study, Titer, Randomized Controlled Trial, factor H-binding protein, Female, Antibody, Adult, Adolescent, Fever, Serogroup B, 030106 microbiology, Meningococcal Vaccines, Meningococcal vaccine, Antibodies, Young Adult, 03 medical and health sciences, Bacterial Proteins, Journal Article, medicine, Antigens, Bacterial, Humans, Meningococcal Infections, Antigens, business.industry, Immunology, biology.protein, Bacterial antigen, business
Abstract

BACKGROUND: MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group B meningococcus.METHODS: We randomly assigned 3596 adolescents (10 to 18 years of age) to receive MenB-FHbp or hepatitis A virus vaccine and saline and assigned 3304 young adults (18 to 25 years of age) to receive MenB-FHbp or saline at baseline, 2 months, and 6 months. Immunogenicity was assessed in serum bactericidal assays that included human complement (hSBAs). We used 14 meningococcal B test strains that expressed vaccine-heterologous factor H-binding proteins representative of meningococcal B epidemiologic diversity; an hSBA titer of at least 1:4 is the accepted correlate of protection. The five primary end points were the proportion of participants who had an increase in their hSBA titer for each of 4 primary strains by a factor of 4 or more and the proportion of those who had an hSBA titer at least as high as the lower limit of quantitation (1:8 or 1:16) for all 4 strains combined after dose 3. We also assessed the hSBA responses to the primary strains after dose 2; hSBA responses to the 10 additional strains after doses 2 and 3 were assessed in a subgroup of participants only. Safety was assessed in participants who received at least one dose.RESULTS: In the modified intention-to-treat population, the percentage of adolescents who had an increase in the hSBA titer by a factor of 4 or more against each primary strain ranged from 56.0 to 85.3% after dose 2 and from 78.8 to 90.2% after dose 3; the percentages of young adults ranged from 54.6 to 85.6% and 78.9 to 89.7%, after doses 2 and 3, respectively. Composite responses after doses 2 and 3 in adolescents were 53.7% and 82.7%, respectively, and those in young adults were 63.3% and 84.5%, respectively. Responses to the 4 primary strains were predictive of responses to the 10 additional strains. Most of those who received MenB-FHbp reported mild or moderate pain at the vaccination site.CONCLUSIONS: MenB-FHbp elicited bactericidal responses against diverse meningococcal B strains after doses 2 and 3 and was associated with more reactions at the injection site than the hepatitis A virus vaccine and saline. (Funded by Pfizer; ClinicalTrials.gov numbers, NCT01830855 and NCT01352845 ).

Published
2017

36. Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018 [Consensus document and recommendations for the prevention of cardiovascular disease in Italy - 2018]

Author

Volpe M., Tocci G., Accettura D., Battistoni A., Costanzo G., Rubattu S., Volpe R., Bellone S., Ricotti R., Bellotti P., Bertolotti M., Modena M. G., Borghi C., Casasco M., Rizzoni D., Consoli A., Coppini R., Galanti G., Lombardi N., Modesti P. A., Mugelli A., Rotella C., Corsini A., Parati G., Perseghin G., Desideri G., Ferri C., Giada F., Icardi G., Orsi A., Monti G., Pedretti R. F. E., Pirro M., Salvetti G., Sarto P., Tassinari F., Trimarco B., de Kreutzenberg S. V., Volpe, M, Tocci, G, Accettura, D, Battistoni, A, Costanzo, G, Rubattu, S, Volpe, R, Bellone, S, Ricotti, R, Bellotti, P, Bertolotti, M, Modena, M, Borghi, C, Casasco, M, Rizzoni, D, Consoli, A, Coppini, R, Galanti, G, Lombardi, N, Modesti, P, Mugelli, A, Rotella, C, Corsini, A, Parati, G, Perseghin, G, Desideri, G, Ferri, C, Giada, F, Icardi, G, Orsi, A, Monti, G, Pedretti, R, Pirro, M, Salvetti, G, Sarto, P, Tassinari, F, Trimarco, B, and de Kreutzenberg, S

Subjects
Multidisciplinary approach, Prevention, Risk factor, Cardiovascular disease
Abstract

Cardiovascular prevention represents a cornerstone of modern strategies to reduce the burden of cardiovascular disease. It is of key importance to prevent cardiovascular diseases and associated events, not only to reduce morbidity and mortality, but also to increase the years of wellness in the aging population and to make the growing socio-economic burden imposed by cardiovascular events more sustainable. The current approach to prevention is based on an integrated use of effective lifestyle measures and, whenever appropriate, of antihypertensive and antidiabetic drugs, lipid-lowering agents and antiplatelet drugs. Given that population characteristics, in terms of ethnicity, demography and lifestyle habits, and healthcare system organizations differ among countries, international guidelines are not always applicable to specific countries and, often, are difficult to translate into daily clinical practice. In order to afford the specific features of Italy, 10 Scientific Societies and Research Institutions, mostly involved in preventive strategies, contributed to the present Italian consensus document, which includes brief, practical recommendations to support the preventive actions within the physician community and the general practice setting.

Published
2018

37. Trend in rifampicin-, multidrug- and extensively drug-resistant tuberculosis in Italy, 2009-2016

Author

Mustazzolu, A., Borroni, E., Cirillo, D. M., Giannoni, F., Iacobino, A., Fattorini, L., Ghisetti, V., Mondo, A., Avolio, M., Barbui, A., Lorenzetti, P., De Renzi, G., Chirillo, M. G., Molinari, G., Camaggi, A., Andreoni, S., Piana, F., Marchese, A., Gritti, P., Icardi, G., Varnier, O., Mazzola, E., Gesu, G., Cichero, P., Lombardi, A., Libanori, E., Viggiani, P., De Lorenzo, S., Pinsi, G., Marone, P., Monzillo, V., Barbarini, D., Farina, C., Arosio, M., Peracchi, M., Manganelli, R., Fabris, C., Di Santolo, M., Busetti, M., Scarparo, C., Sartor, A., Pedrotti, C., Caola, I., Frizzera, E., Dal Monte, P., Pietrosemoli, P., Pecorari, M., Fabio, A., La Regina, A., Matteucci, M., Piersimoni, C., Bartolesi, A., Mannino, R., Simonetti, T., Tortoli, E., Rindi, L., Mencacci, A., Cenci, E., Luciano, E., Mazzolla, R., Sanguigni, I., Parisi, G., Chiaradonna, P., Altieri, A. M., D'Arezzo, S., Mazzarelli, A., Di Caro, A., Bordi, E., Sali, M., Delogu, G., Sanguinetti, M., Russo, C., Coltella, L., Ciocco, A., Meledandri, M., Gambi, A., Tomei, G., Conte, M., Santoro, G., Del Giudice, A., Nuzzolese, N., Vitullo, E., Sinno, A., Buono, L., Costa, D., Grimaldi, A., Di Taranto, A., De Nittis, R., Palumbo, G., Dodaro, S., Giraldi, C., Cavalcanti, P., Nistico, S., Vinci, L., Di Naso, C., Bonura, C., Maida, C. M., Mammina, C., Podda, G. S., Caddeu, R., Mustazzolu A., Borroni E., Cirillo D.M., Giannoni F., Iacobino A., Fattorini L., Ghisetti V., Mondo A., Avolio M., Barbui A., Lorenzetti P., De Renzi G., Chirillo M.G., Molinari G., Camaggi A., Andreoni S., Piana F., Marchese A., Gritti P., Icardi G., Varnier O., Mazzola E., Gesu G., Cichero P., Lombardi A., Libanori E., Viggiani P., De Lorenzo S., Pinsi G., Marone P., Monzillo V., Barbarini D., Farina C., Arosio M., Peracchi M., Manganelli R., Fabris C., Di Santolo M., Busetti M., Scarparo C., Sartor A., Pedrotti C., Caola I., Frizzera E., Dal Monte P., Pietrosemoli P., Pecorari M., Fabio A., La Regina A., Matteucci M., Piersimoni C., Bartolesi A., Mannino R., Simonetti T., Tortoli E., Rindi L., Mencacci A., Cenci E., Luciano E., Mazzolla R., Sanguigni I., Parisi G., Chiaradonna P., Altieri A.M., D'Arezzo S., Mazzarelli A., Di Caro A., Bordi E., Sali M., Delogu G., Sanguinetti M., Russo C., Coltella L., Ciocco A., Meledandri M., Gambi A., Tomei G., Conte M., Santoro G., Del Giudice A., Nuzzolese N., Vitullo E., Sinno A., Buono L., Costa D., Grimaldi A., Di Taranto A., De Nittis R., Palumbo G., Dodaro S., Giraldi C., Cavalcanti P., Nistico S., Vinci L., Di Naso C., Bonura C., Maida C.M., Mammina C., Podda G.S., and Caddeu R.

Subjects
0301 basic medicine, Pulmonary and Respiratory Medicine, Extensively Drug-Resistant Tuberculosis, Antitubercular Agents, Emigrants and Immigrants, Humans, Italy, Mycobacterium tuberculosis, Rifampin, Tuberculosis, Multidrug-Resistant, 03 medical and health sciences, 0302 clinical medicine, polycyclic compounds, medicine, Tuberculosis, biology, business.industry, Extensively drug-resistant tuberculosis, Multidrug-Resistant, medicine.disease, biology.organism_classification, Virology, 030104 developmental biology, 030228 respiratory system, business, Rifampicin, medicine.drug
Abstract

In Italy, rifampicin-resistant and MDR-TB were high in foreign-born persons, but decreased from 2009 to 2016

Published
2018

39. HPV Vaccination Concepts in the Reality of Today

Author

Paderno, A, Garolla, A, Pecorelli, S, Lombardi, A, Pinto, C, Icardi, G, Bonetti, F, Mennini, F, Conversano, M, Isidori, A, Mariani, L, Rezza, G, and Peracino, A

Subjects
Settore SECS-P/03 - Scienza delle Finanze
Published
2019

43. Surveillance and prevention of viral hepatitis A and B in Europe: lessons learnt and considerations for the future: Workshop: The comparative sero-epidemiology of Hepatitis A and B in 14 countries participating in the European Sero-Epidemiology Network (ESEN2)

Author

Nardone, A, Andrews, N, Edmunds, WJ, Kafatos, G, Miller, E, Anastassopoulou, C, Hatzakis, A, De Cock, LD, Vranckx, R, Theeten, H, van Damme, P, Nemecek, V, Kriz, B, Davidkin, Hellenbrand, W, Thierfelder, W, Carton, M, OʼFlanagan, D, Jones, L, Cohen, D, Ansaldi, F, Bruzzone, B, Crovari, P, Icardi, G, Rota, C, Mossong, J, Schneider, F, Berbers, G, de Melker, H, Amato-Gauci, A, Barbara, C, Butur, D, Pistol, A, Slacikova, M, Sobotova, Z, de Ory, F, and Echevarria, JM

Published
2004

45. Vaccinazioni: stato dell’arte, falsi miti e prospettive. Il ruolo chiave della prevenzione

Author

Guerra, R., Ricciardi, W., Siliquini, R., D’Ancona, P., Iannazzo, S., Mantovani, A., Poscia, A., Sisti, L., Cicconi, M., De Waure, C., Di Pietro Ml, Teleman, A., Adamo, G., Marzuillo, C., Sturabotti, G., Villari, P., Vitale, F., Costantino, C., Restivo, V., Mazzucco, W., Mennini, F., Franco, E., Vaccaro, K., Boccalini, S., Bonanni, P., Ferro, A., Castiglia, P., Siddu, A., Panatto, D., Amicizia, D., Arata, L., Zangrillo, F., Domnich, A., Gasparini, R., Barnini, C., Giannesi, C., Onder, L., Milillo, G., DI MAIO, M., Conforti, G., Bernabei, R., Francia, F., Boda, G., Icardi, G., Signorelli, C., Guerra, R., Ricciardi, W., Siliquini, R., D’Ancona, P., Iannazzo, S., Mantovani, A., Poscia, A., Sisti, L., Cicconi, M., De Waure, C., Di Pietro Ml, Teleman, A., Adamo, G., Marzuillo, C., Sturabotti, G., Villari, P., Vitale, F., Costantino, C., Restivo, V., Mazzucco, W., Mennini, F., Franco, E., Vaccaro, K., Boccalini, S., Bonanni, P., Ferro, A., Castiglia, P., Siddu, A., Panatto, D., Amicizia, D., Arata, L., Zangrillo, F., Domnich, A., Gasparini, R., Barnini, C., Giannesi, C., Onder, L., Milillo, G., DI MAIO, M., Conforti, G., Bernabei, R., Francia, F., Boda, G., Icardi, G., and Signorelli, C.

Subjects
Vaccinazione, prevenzione, vaccini, Settore MED/42 - Igiene Generale E Applicata
Abstract

La pratica vaccinale in Italia è organizzativamente incardinata all’interno del Servizio Sanitario Nazionale (SSN) e nei Servizi Sanitari Regionali (SSR). I luoghi “classici” in cui viene effettuata la procedura/prestazione vaccinale sono i servizi di vaccinazione della Aziende Sanitarie Locali (ASL) o Provinciali (ASP) delle varie Regioni.

Published
2017

47. Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older

Author

Cunningham, A. L., Lal, H., Kovac, M., Chlibek, R., Hwang, S. -J., Diez-Domingo, J., Godeaux, O., Levin, M. J., Mcelhaney, J. E., Puig-Barbera, J., Vanden Abeele, C., Vesikari, T., Watanabe, D., Zahaf, T., Ahonen, A., Athan, E., Barba-Gomez, J. F., Campora, L., De Looze, F., Downey, H. J., Ghesquiere, W., Gorfinkel, I., Korhonen, T., Leung, E., Mcneil, S. A., Oostvogels, L., Rombo, L., Smetana, J., Weckx, L., Yeo, W., Heineman, T. C., Athan, E, Cunningham, Al, de Looze, F, Eizenberg, P, Yeo, W, Avelino-Silva, Tj, Neto, Jl, Santos, Rr, Weckx, L, Zerbini, Ca, Gauthier, Js, Ghesquiere, W, Gorfinkel, I, Mcelhaney, Je, Mcneil, Sa, Toma, A, Chlibek, R, Smetana, J, Poder, A, Ahonen, A, Forsten, A, Karppa, T, Korhonen, T, Seppä, I, Vesikari, T, Esen, M, Schwarz, Tf, Leung, E, Desole, Mg, Icardi, G, Pellegrino, A, Staniscia, T, Volpi, A, Ikematsu, H, Watanabe, D, Choi, Ws, Barba-Gomez, Jf, Mascarenas de Los Santos, A, Tinoco, Jc, Brotons, C, Caso, C, Diez-Domingo, J, Narejos Perez, S, Puig-Barberà, J, Rodriguez de la Pinta ML, Berglund, J, Blom, Kb, Liu, B, Pauksens, K, Rombo, L, Hwang, Sj, Thompson, A, Andrews, C, Jackson Downey, H, Freedman, M, Levin, M, Arbi, Mb, Campora, L, Catteau, G, Curran, D, Godeaux, O, Heineman, Tc, Kovac, M, Lal, H, Marion, S, Oostvogels, L, Oujaa, M, Ravault, S, Abeele, Cv, Vastiau, I, Zahaf, T, Junqueira, T, Berndtsson Blom, K, Downey, H, Rodriguez, Ml, Zerbini, C, Heineman, T, Levin, Mj, Puig, J, and Heineman, Tc.

Subjects
Male, Risk, 0301 basic medicine, Subunit, medicine.medical_specialty, Herpes Zoster Vaccine, Neuralgia, Postherpetic, Kaplan-Meier Estimate, Placebo, Herpes Zoster, law.invention, 03 medical and health sciences, 0302 clinical medicine, Double-Blind Method, Randomized controlled trial, law, Internal medicine, 80 and over, medicine, Humans, 030212 general & internal medicine, Aged, Aged, 80 and over, Vaccines, business.industry, Postherpetic neuralgia, General Medicine, Middle Aged, medicine.disease, Vaccine efficacy, Surgery, Clinical trial, 030104 developmental biology, Female, Vaccines, Subunit, Neuralgia, Zoster vaccine, Postherpetic, business, medicine.drug
Abstract

BACKGROUND A trial involving adults 50 years of age or older (ZOE-50) showed that the herpes zoster subunit vaccine (HZ/su) containing recombinant varicella-zoster virus glycoprotein E and the AS01(B) adjuvant system was associated with a risk of herpes zoster that was 97.2% lower than that associated with placebo. A second trial was performed concurrently at the same sites and examined the safety and efficacy of HZ/su in adults 70 years of age or older (ZOE-70). METHODS This randomized, placebo-controlled, phase 3 trial was conducted in 18 countries and involved adults 70 years of age or older. Participants received two doses of HZ/su or placebo (assigned in a 1: 1 ratio) administered intramuscularly 2 months apart. Vaccine efficacy against herpes zoster and postherpetic neuralgia was assessed in participants from ZOE-70 and in participants pooled from ZOE-70 and ZOE-50. RESULTS In ZOE-70, 13,900 participants who could be evaluated (mean age, 75.6 years) received either HZ/su (6950 participants) or placebo (6950 participants). During a mean follow-up period of 3.7 years, herpes zoster occurred in 23 HZ/su recipients and in 223 placebo recipients (0.9 vs. 9.2 per 1000 person-years). Vaccine efficacy against herpes zoster was 89.8% (95% confidence interval [CI], 84.2 to 93.7; P

Published
2016

48. Influenza Vaccination in Italian Healthcare Workers (2018–2019 Season): Strengths and Weaknesses. Results of a Cohort Study in Two Large Italian Hospitals

Author

Panatto, D., Lai, P. L., Mosca, S., Lecini, E., Orsi, A., Signori, A., Castaldi, S., Pariani, E., Pellegrinelli, L., Galli, C., Anselmi, G., Icardi, G., Sticchi, L., Zangrillo, F., Iovine, M., Marchini, F., Grammatico, F., Pennati, B. M., Zacconi, M., Tassinari, F., Arcuri, C., Canepa, P., Caligiuri, P., Rappazzo, E., Guarona, G., Barisione, G., Varesano, S., Cavazzana, L., Carnevali, D., Del Castillo, G., Forni, G., Gandolfi, C., Grimoldi, L., Magnoni, P., Mosillo, M., Pietronigro, A., Principi, N., Tiwana, N., Battistini, A., Di Bella, A. M., Guglielmi, B., Bellina, D., Talamini, A., Daturi, V., and Ziferro, R.

Subjects
0301 basic medicine, Influenza vaccine, Healthcare workers, Influenza, Influenza vaccination, Influenza vaccination coverage, Laboratory-confirmed influenza, 030106 microbiology, Immunology, lcsh:Medicine, laboratory-confirmed influenza, Article, 03 medical and health sciences, 0302 clinical medicine, Environmental health, Drug Discovery, Health care, Medicine, Pharmacology (medical), 030212 general & internal medicine, Pharmacology, influenza vaccination coverage, healthcare workers, business.industry, Proportional hazards model, lcsh:R, Confounding, virus diseases, Influenza a, influenza vaccination, 3. Good health, Vaccination, Infectious Diseases, influenza, business, Strengths and weaknesses, Cohort study
Abstract

Background: Annual vaccination is the most effective way to combat influenza. As influenza viruses evolve, seasonal vaccines are updated annually. Within the European project Development of Robust and Innovative Vaccine Effectiveness (DRIVE), a cohort study involving Italian healthcare workers (HCWs) was carried out during the 2018-2019 season. Two aims were defined: to measure influenza vaccine effectiveness (IVE) against laboratory-confirmed influenza cases and to conduct an awareness-raising campaign to increase vaccination coverage. Methods: Each subject enrolled was followed up from enrollment to the end of the study. Each HCW who developed ILI was swabbed for laboratory confirmation of influenza. Influenza viruses were identified by molecular assays. A Cox regression analysis, crude and adjusted for confounding variables, was performed to estimate the IVE. Results: Among the 4483 HCWs enrolled, vaccination coverage was 32.5%, and 308 ILI cases were collected: 23.4% were positive for influenza (54.2% A(H1N1) pdm09, 45.8% A(H3N2)). No influenza B viruses were detected. No overall IVE was observed. Analyzing the subtypes of influenza A viruses, the IVE was estimated as 45% (95% CI: -59 to 81) for A(H1N1) pdm09. Conclusions: Vaccination coverage among HCWs increased. Study difficulties and the circulation of drifted variants of A(H3N2) could partly explain the observed IVE.

Published
2020

49. Anti-polio vaccinations in the third millennia

Author

Icardi, G and Tassinari, F

Subjects
Poliovirus Vaccine, Inactivated, Epidemiology, Polio, Poliomyelitis, Vaccinations, Time Factors, Immunization Programs, Poliovirus Vaccine, Oral, Humans, Disease Eradication, Global Health
Abstract

Poliomyelitis is a highly infectious viral disease, which mainly affects young children. In 1988, the World Health Assembly adopted a resolution that committed all countries to polio eradication by the year 2000, launching the Global Polio Eradication Initiative. The last naturally occurring case of wild polio virus type 2 infection was in October 1999 while the last case of wild polio virus type 3 was recorded in November 2012. In 2016 there were the lowest number of polio cases in recorded history (just 37) and this year we expect even fewer cases. Until the end of October 2017 only 12 cases were reported (the previous year, in this same period, 27 cases had been recorded). The eradication program did not progress smoothly: fundamentalism; religious opposition; civil war; outbreaks of other infectious diseases and circulating vaccine-derived polioviruses may favor the failure of vaccination programs. Through the enormous progress toward polio eradication made in these last years, such as the switch from the trivalent oral poliovirus vaccine to the bivalent oral poliovirus vaccine and the certification of the eradication of the wild polio virus type 2; the eradication efforts are at their final chapter, otherwise known as the polio endgame.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results